C
ABMD

Cerebellum’s Abiomed Inc ABMD Stock Holding History

Cerebellum’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-679
Closed -$127K – 617
2020
Q2 		$127K Buy
+679
New +$136K 0.09% 219
2019
Q3 		– Sell
-1,347
Closed -$351K – 512
2019
Q2 		$351K Buy
1,347
+194
+17% +$51.5K 0.29% 137
2019
Q1 		$329K Buy
1,153
+349
+43% +$116K 0.29% 173
2018
Q4 		$261K Buy
+804
New +$279K 0.18% 94
2018
Q3 		– Sell
-369
Closed -$151K – 532
2018
Q2 		$151K Buy
+369
New +$134K 0.25% 320
2018
Q1 		– Sell
-679
Closed -$127K – 556
2017
Q4 		$127K Buy
+679
New +$127K 0.09% 219

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cerebellum's ABMD Position: Q3 2020 in Review

Cerebellum sold out of Abiomed Inc (ABMD) in Q3 2020, closing a stake of 679 shares — an estimated $127K sold.

Cerebellum first reported a position in ABMD in Q4 2017 and held it in 6 quarters. The position peaked at $351K in Q2 2019. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2020.

  • Cerebellum reported no remaining Abiomed Inc position as of Q3 2020 after selling out during the quarter.
  • Cerebellum sold 679 Abiomed Inc shares in Q3 2020, an estimated $127K.
  • Cerebellum first reported a position in Abiomed Inc in Q4 2017 and held it in 6 quarters.
  • Cerebellum's Abiomed Inc position peaked at $351K in Q2 2019.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2020.

Based on Cerebellum's 13F filing for Q3 2020, filed 21 Oct 2020.